| P50 | author | Annibale Donini | Q44920308 |
| P2093 | author name string | Walter Bugiantella | |
| | Emanuel Cavazzoni | |
| | Luigina Graziosi | |
| | Maria Silvia Franceschini | |
| P2860 | cites work | Management of drainage for malignant ascites in gynaecological cancer | Q24240934 |
| | The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 |
| | Matrix metalloproteinase inhibitors | Q33538437 |
| | Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer | Q34005265 |
| | Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study | Q34049477 |
| | The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female | Q34090877 |
| | Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy. | Q34186644 |
| | Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma | Q34562049 |
| | Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy | Q34618277 |
| | The current and future management of malignant ascites | Q35112307 |
| | Monoclonal antibodies in gynecological cancer: a critical point of view | Q35659915 |
| | Management of ascites due to gastrointestinal malignancy | Q35789515 |
| | Malignant ascites: past, present, and future | Q35803073 |
| | VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence | Q73858011 |
| | Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites | Q74250838 |
| | A survey of practice in management of malignant ascites | Q77297831 |
| | Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach | Q77878244 |
| | Markedly elevated levels of vascular endothelial growth factor in malignant ascites | Q77914895 |
| | Intracavitary thio-TEPA for malignant effusions | Q79401237 |
| | Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery | Q79914655 |
| | Comparison of percutaneous management techniques for recurrent malignant ascites | Q80825435 |
| | A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients | Q81885014 |
| | Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites | Q83187433 |
| | Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer | Q83426498 |
| | Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients | Q84444104 |
| | Intracavitary Thiotepa in Malignant Pleural and Peritoneal Effusions | Q93791875 |
| | Management of malignant pleural effusions and ascites | Q36082953 |
| | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study | Q36105171 |
| | Malignant ascites: systematic review and guideline for treatment. | Q36376629 |
| | The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy | Q36466745 |
| | Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | Q36754883 |
| | Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. | Q37425849 |
| | Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality | Q37498106 |
| | Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? | Q37653357 |
| | Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. | Q37812968 |
| | Cetuximab in the treatment of patients with colorectal cancer | Q37873948 |
| | Recurrent ovarian cancer: when and how to treat | Q37951860 |
| | Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report | Q39302590 |
| | Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. | Q39333446 |
| | On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? | Q40104058 |
| | Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. | Q40456974 |
| | The past, the present and future of the OK-432 therapy for patients with malignant effusions. | Q40831746 |
| | Malignant ascites | Q41000476 |
| | Percutaneous management of malignant fluid collections | Q41971514 |
| | Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. | Q43130795 |
| | Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. | Q43469448 |
| | Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy | Q43533893 |
| | Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial | Q43693195 |
| | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. | Q43703526 |
| | Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. | Q44235624 |
| | Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effe | Q44393350 |
| | Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. | Q44407469 |
| | New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival | Q44670265 |
| | Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics | Q46715321 |
| | Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. | Q46944790 |
| | Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. | Q53638819 |
| | Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites | Q57942624 |
| | PARACENTESIS VERSUS DIURETICS IN THE TREATMENT OF CIRRHOTICS WITH TENSE ASCITES | Q57942641 |
| | Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study | Q58025148 |
| | Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer | Q61843291 |
| | A pilot study of intraperitoneal cisplatin in the management of gastric cancer | Q61868362 |
| | Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer | Q68588470 |
| | Neutrophil-mediated tumor cell destruction in cancer ascites | Q70366731 |
| | Intracavitary chromic phosphate (32p) colloidal suspension therapy | Q70998232 |
| | Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally | Q71507617 |
| | Matrix metalloproteinase inhibitors: a novel class of anticancer agents | Q71773749 |
| | Intracavitary administration of radioactive isotopes in the control of effusions due to cancer:Results in 267 patients | Q72782446 |
| | Paracentesis--an effective method of symptom control in the palliative care setting? | Q73549864 |
| | Use of nitrogen mustard in treatment of serous effusions of neoplastic origin | Q73851004 |
| P433 | issue | 1 | |
| P921 | main subject | pathophysiology | Q1135939 |
| P304 | page(s) | 1-9 | |
| P577 | publication date | 2012-03-31 | |
| P1433 | published in | International Journal of Clinical Oncology | Q15758148 |
| P1476 | title | Malignant ascites: pathophysiology and treatment | |
| P478 | volume | 18 | |